<DOC>
	<DOCNO>NCT02172976</DOCNO>
	<brief_summary>In multicenter study , patient resectable pancreatic carcinoma treat ( ) surgery follow 6 cycle gemcitabine ( b ) 6 cycle FOLFIRINOX follow surgery follow 6 cycle FOLFIRINOX . The overall survival therapy compare well parameter .</brief_summary>
	<brief_title>Randomized Multicenter Phase II/III Study With Adjuvant Gemcitabine Versus Neoadjuvant / Adjuvant FOLFIRINOX Resectable Pancreas Carcinoma</brief_title>
	<detailed_description>This phase II/III randomize multicenter study . Patients resectable pancreatic carcinoma randomize Arm A ( surgery plus adjuvant gemcitabine , 6 cycle ) Arm B ( 6 cycle FOLFIRINOX neoadjuvant , 6 cycle FOLFIRINOX adjuvant ) . Primary endpoint overall survival , secondary endpoint progression-free survival , perioperative morbidity mortality , rate R0 resection , tolerability feasibility neoadjuvant FOLFIRINOX others .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>1 . Histologically confirm ductal adenocarcinoma pankreas . For histological confirmation , max . 3 test allow . If confirmation carcinoma possible , patient include study . 2 . Radiological confirmation locally limited curativ resectable ( primarily resectale borderline situation ) pankreas carcinoma without distant metastasis . 3. prior pancreas resection 4. prior cytostatic chemotherapy 5 . Bilirubin &lt; 1,6 mg/dl 6. female male patient &gt; 18 year use contraception 7 . ECOG ≤ 1 8. medical resectability 9. granulocyte &gt; 1.500/µl 10. thrombocyte &gt; 100.000/µl 11. hemoglobin ≥ 8,0 g/dl 12. serumcreatinine ≤ 1.5x normal value CreatinineClearance &gt; 50 ml/min 13. write informed consent 1 . Endocrine acinar pancreas carcinoma 2. locally advanced inoperable stage : nonresectable infiltration V. porta longway infiltration A. mesenterica superior infiltration Truncus coeliacus . 3. distant metastasis 4 . Relapse 5. prior radiotherapy measurable lesion 6. peritonealcarcinosis 7. malignant secondary disease , date back &lt; 5 year ( exeption : insitucarcinoma cervix , adequately treat skin basal cell carcinoma ) 8. contraindication operative resection 9 . ECOG ≥ 2 10. severe liver dysfunction ( AST/ALT &gt; 3,5xULN , AP &gt; 6xULN , Bilirubin &gt; 1,5xULN ) 11 . Transhepatic drainage 12. active CHD ( symptoms present ) , cardiomyopathy heart insufficiency stage IIIIV accord NYHA EF &lt; 45 % 13. severe nonsurgical accompanying disease acute infection 14. chronic diarrhea 15. chronic inflammable gastrointestinal disease 16. peripheral polyneuropathy &gt; NCI grade II 17. pregnancy lactation 18. hypersensibility contraindication Gemcitabine , Oxaliplatin , Natriumfolinate , Irinotecan 5Fluorouracil 19. participation another interventional trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>pancreas cancer</keyword>
	<keyword>neoadjuvant chemotherapy</keyword>
	<keyword>Folfirinox</keyword>
	<keyword>gemcitabine</keyword>
</DOC>